Effects of interleukin-3 on myelosuppression induced by chemotherapy for ovarian cancer and small cell undifferentiated tumours.

by Dercksen, M. W., Hoekman, K., ten Bokkel Huinink, W. W., Rankin, E. M., Dubbelman, R., van Tinteren, H., Wagstaff, J., Pinedo, H. M.
Published 1993

Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

by Herben, V. M., ten Bokkel Huinink, W. W., Dubbelman, A. C., Mandjes, I. A., Groot, Y., van Gortel-van Zomeren, D. M., Beijnen, J. H.
Published 1997

Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Coop...

by de Wit, R., Stoter, G., Sleijfer, D. T., Neijt, J. P., ten Bokkel Huinink, W. W., de Prijck, L., Collette, L., Sylvester, R.
Published 1998

Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.

by de Wit, R., Collette, L., Sylvester, R., de Mulder, P. H., Sleijfer, D. T., ten Bokkel Huinink, W. W., Kaye, S. B., van Oosterom, A. T., Boven, E., Stoter, G.
Published 1998

Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.

by McLeod, H. L., Murray, L. S., Wanders, J., Setanoians, A., Graham, M. A., Pavlidis, N., Heinrich, B., ten Bokkel Huinink, W. W., Wagener, D. J., Aamdal, S., Verweij, J.
Published 1996

Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.

by Sternberg, C. N., ten Bokkel Huinink, W. W., Smyth, J. F., Bruntsch, V., Dirix, L. Y., Pavlidis, N. A., Franklin, H., Wanders, S., Le Bail, N., Kaye, S. B.
Published 1994

Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tra...

by de Wit, R., Stoter, G., Sleijfer, D. T., Kaye, S. B., de Mulder, P. H., ten Bokkel Huinink, W. W., Spaander, P. J., de Pauw, M., Sylvester, R.
Published 1995

Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous...

by de Wit, R., Sylvester, R., Tsitsa, C., de Mulder, P. H., Sleyfer, D. T., ten Bokkel Huinink, W. W., Kaye, S. B., van Oosterom, A. T., Boven, E., Vermeylen, K., Stoter, G.
Published 1997

Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial.

by Elferink, F., van der Vijgh, W. J., ten Bokkel Huinink, W. W., Vermorken, J. B., Klein, I., Winograd, B., Knobf, M. K., Simonetti, G., Gall, H. E., McVie, J. G.
Published 1987